Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer
Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the results from the randomized controlled Phase II clinical trial, NIPU, are published in the European Journal of Cancer. The trial investigates the effect of…
Narayana Health Initiates Phase II Clinical Trial of CAR-T
Narayana Health, one of the leading healthcare chain in India, today announced that they have offered support to Immuneel Therapeutics, to build the most advanced CAR-T cell laboratory at the Narayana Health city Bengaluru. With this Narayana Health will offer…
